I sat down with two outstanding ADDF-funded researchers recently to talk about the latest news on their cutting-edge work, the inspiration for their ideas, and when we can expect results from their latest trials.  ..read more

Robust Alzheimer’s Clinical Trial Portfolio Provides More Opportunities for Patient Participation ..read more

The FDA made a landmark decision on June 7, approving aducanumab (Aduhelm™, Biogen) for the treatment of Alzheimer’s disease. Aducanumab is the first new Alzheimer’s treatment in 17 years and the first ever shown to modify the course of the disease ..read more

22nd International Conference on Alzheimer’s Drug Discovery ..read more

Earlier this year, two outstanding researchers, Paul Fish, Ph.D., and Paul Worley, M.D., were selected by the ADDF and Harrington Discovery Institute to receive ADDF-Harrington Scholar Awards ..read more

The FDA approved aducanumab (Aduhelm®), an antibody that clears amyloid plaques from the brain, in June.  ..read more

Alzheimer’s Drug Discovery Foundation Funds Second Phase of Global Alzheimer’s Prevention FINGER TRIAL ..read more

Five previous winners of the prestigious Melvin R. Goodes Prize came together in New York City recently to honor this year’s winner, Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, and to discuss how their research is working toward the same goal – to conquer Alzheimer’s ..read more